Physician profile
Walid A Abboud
NPI 1245295559
$4,513.20
in general payments reported to CMS, 2019-2025
9 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $529 · 2021: $1,928 · 2022: $426 · 2023: $712 · 2024: $516 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,849.15 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $1,312.67 | 2020-2024 | Nexlizet, Nexletol |
| Astrazeneca Pharmaceuticals LP | $806.83 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $411.30 | 2021-2022 | |
| Abiomed | $53.08 | 2023 | Impella |
| Novartis Pharmaceuticals Corporation | $24.09 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.13 | 2025 | Lifevest |
| Novo Nordisk INC | $17.23 | 2023 | Rybelsus, Ozempic |
| Abbvie INC. | $16.72 | 2023 | Teflaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walid Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.